September 30, 2025 — Gilead’s Epclusa (sofosbuvir/velpatasvir, 400mg/100mg) continues to reshape hepatitis C management worldwide. As the first and only all-oral, pan-genotypi...
The Global Cancer Landscape: From First- to Third-Generation Targeted Drugs — How Medicine Is Changing the Fate of CancerNot long ago, a cancer diagnosis was almost a death senten...